Business context and reporting period
Briacell Therapeutics Corp. filed this Form 10-K for the fiscal year ended July 31, 2022, with comparative 2021 results. Figures are in U.S. dollars unless stated otherwise. The company is a pre-revenue immuno-oncology biotechnology developer; it reported no product revenue.
Its lead candidate, Bria-IMT, is an investigational whole-cell immunotherapy for advanced breast cancer, being studied with checkpoint inhibitors. Other programs include Bria-OTS and a companion diagnostic, BriaDx, plus early-stage PKCδ inhibitor and other immunotherapy programs.
Financial performance and liquidity
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $8.02 million | $2.02 million |
| General and administrative expense | $7.27 million | $4.96 million |
| Operating loss | $15.29 million | $6.98 million |
| Net loss | $26.84 million | $13.82 million |
| Net loss per share, basic and diluted | $1.73 | $3.06 |
| Net cash used in operating activities | $12.48 million | $7.75 million |
| Cash and cash equivalents, July 31 | $41.04 million | $57.27 million |
| Working capital, July 31 | $41.41 million | $57.24 million |
Cash and cash equivalents declined by $16.23 million during FY2022. Financing activities used $3.74 million, including $10.17 million for the share-and-warrant repurchase program, partly offset by $6.51 million from warrant exercises. The company reported $0.94 million of current liabilities and no government loans outstanding at year-end. It did report a $31.31 million warrant liability, largely reflecting warrants classified and remeasured as liabilities; this is distinct from conventional borrowing.
No profit margin is meaningful because the company had no revenue. Management said existing resources were expected to meet anticipated liquidity needs for at least 12 months from issuance of the financial statements, but also said additional capital would be needed for longer-term research and development. The financial statements use the going-concern basis.
Material changes versus FY2021
- Net loss increased by $13.02 million, or about 94%; operating loss more than doubled.
- R&D expense rose about 297%, which management attributed to restarting clinical trials, greater laboratory activity, and additional lab staff.
- G&A expense increased about 47%, mainly due to increased staffing, professional and consulting costs, and share-based compensation.
- Net financial expense rose to $11.55 million from $6.84 million. The 2022 amount included an $11.66 million charge from warrant-liability fair-value changes; the valuation is sensitive to share price and other assumptions.
- Operating cash use increased by $4.73 million. Cash fell despite $6.51 million of warrant-exercise proceeds, in part because of the repurchases.
Outlook, commentary, risks and unusual items
- Clinical development: The filing describes the Bria-IMT combination study with Incyte’s retifanlimab as ongoing and anticipated further safety and efficacy data during 2022–2023. After year-end, the company reported completion of the Phase I portion, with 12 patients and no dose-limiting toxicities, and described Phase II evaluation as progressing. These are company-reported early-stage results, not evidence of regulatory approval or established efficacy.
- Regulatory status: Bria-IMT received FDA Fast Track designation for metastatic breast cancer. Fast Track may facilitate development or review but is not marketing approval. The company planned discussions with FDA on a registration-study design; timing and design remained uncertain.
- Other programs: Bria-OTS was in development, and the company described planned clinical evaluation and manufacturing work. PKCδ inhibitors remained preclinical; the company noted its lead compound BC106 had solubility limitations and further optimization was needed.
- Funding and execution: BriaCell has a history of losses, no product sales, and expects continuing development spending. It may need further financing, potentially on dilutive terms. It depends on third parties for manufacturing, trials, and other key activities.
- Clinical and market risks: Small, uncontrolled early studies may not predict later outcomes; safety, efficacy, recruitment, regulatory approval, commercialization, and reimbursement are uncertain. The filing cited COVID-19-related delays of at least one quarter and risks from inflation, market volatility, and geopolitical disruption.
- Controls: Management concluded disclosure controls were ineffective as of July 31, 2022 because of material weaknesses, including insufficient segregation of duties, documentation, access reviews, vendor-control assessment, and written procedures. Remediation was underway; effectiveness was not established.
- Contingency: Alpha Capital Anstalt litigation over a loan and warrant dispute remained pending. BriaCell disputed the claims and assessed, based on counsel’s advice, that it was more likely than not it would not have to pay; the outcome could not be assured.
- Unusual accounting and dilution: The company transitioned from IFRS to U.S. GAAP after losing foreign-private-issuer status, changing warrant accounting and creating a significant liability remeasurement. As of October 27, 2022, it reported 15.52 million shares outstanding and substantial outstanding options and warrants, presenting potential dilution.
Most important facts for investors to verify
- Current cash balance, actual cash burn, financing needs, and whether the stated 12-month liquidity expectation remains valid.
- Updated Bria-IMT Phase II enrollment, prespecified endpoints, controlled efficacy and survival data, and FDA feedback on any registration study.
- Reconciliation of warrant-liability fair-value movements and their effect on reported net loss versus cash burn.
- Progress and evidence of remediation of the disclosed material weaknesses in financial reporting controls.
- Status and potential financial exposure of the Alpha Capital litigation, as well as the fully diluted share count and any subsequent securities issuances.